SCHEMBL25545933

SCHEMBL25545933

COc1cccc(-c2nc(Cl)sc2CC(C)C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.44
MAPT P10636 2/20 0.44
KDM4E B2RXH2 1/20 0.44
LMNA P02545 1/20 0.44
FBP1 P09467 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.41
RAB9A P51151 3/20 0.41
NFKB1 P19838 2/20 0.41
NFKB2 Q00653 2/20 0.41
RELA Q04206 2/20 0.41
TP53 P04637 3/20 0.41
ALDH1A1 P00352 2/20 0.40
HPGD P15428 1/20 0.40
NPC1 O15118 2/20 0.40
DPP4 P27487 1/20 0.40
ADORA2A P29274 2/20 0.40
PDE4B Q07343 3/20 0.39
ADORA1 P30542 1/20 0.39
DYRK1A Q13627 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25546361 0.89 FBP1 (0.43) MAPTLMNAFBP1PDE4B
SCHEMBL25546032 0.88 KMT2A (0.47) TDP1MAPTKDM4EFBP1SMN1; SMN2
SCHEMBL25546364 0.87 FBP1 (0.45) KDM4EFBP1SMN1; SMN2RAB9ATP53
SCHEMBL25545944 0.87 FBP1 (0.44) TDP1MAPTKDM4ELMNAFBP1
SCHEMBL25546356 0.85 KDM4E (0.46) MAPTKDM4ELMNAFBP1SMN1; SMN2
SCHEMBL25546513 0.84 SMN1; SMN2 (0.47) KDM4EFBP1SMN1; SMN2
SCHEMBL29224039 0.84 FBP1 (0.40) TDP1MAPTKDM4ELMNAFBP1
SCHEMBL25546355 0.84 FBP1 (0.42) KDM4EFBP1SMN1; SMN2DPP4
SCHEMBL25546349 0.83 FBP1 (0.39) FBP1KCNA5
SCHEMBL25546332 0.82 FBP1 (0.41) LMNAFBP1SMN1; SMN2NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 TDP1 1025/4885MAPT 2231/4885KDM4E 710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.